Effects of the antiestrogen EM-800 (SCH 57050) and cyclophosphamide alone and in combination on growth of human ZR-75-1 breast cancer xenografts in nude mice

Cancer Research

Volumn 59, Issue 20, 1999, Pages 5176-5180

  Gutman, Matthieu ^b   Couillard, Steeve ^b   Labrie, Fernand ^b   Candas, Bernard ^b   Labrie, Claude ^a  

^a LAVAL UNIVERSITY   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 METHYL 2 [4 [2 (1 PIPERIDINYL)ETHOXY]PHENYL] 7 PIVALOYLOXY 2H 1 BENZOPYRAN 3 YLPHENYL] PIVALATE; CYCLOPHOSPHAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CONTROL; CONTROLLED STUDY; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; NUDE MOUSE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TUMOR REGRESSION; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZOPYRANS; BODY WEIGHT; CYCLOPHOSPHAMIDE; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; ORGAN SIZE; PROPIONATES; TRANSPLANTATION, HETEROLOGOUS; UTERUS;

EID: 0032718892     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Landis, S. H., Murray, T., Bolden, S., and Wingo, P. A. Cancer Statistics. CA Cancer J. Clin., 49: 8-31, 1999.
2. McGuire, W. L., Carbone, P. P., Seard, M. E., and Esche, G. C. Estrogen receptors in human breast cancer: an overview. In: W. L. McGuire, P. P. Carbone, and E. P. Vollmer (eds.), Estrogen Receptors in Human Breast Cancer, pp. 1-7. New York: Raven Press, 1975.
3. Green, S., Walter, P., Kumar, V., Krust, V., Bornert, J. M., Argos, P., and Chambon, P. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature (Lond.), 320: 134-139, 1986.
4. Gronemeyer, H., Benhamou, B., Berry, M., Bocquel, M. T., Gofflo, D., Garcia, T., Lerouge, T., Metzger, D., Meyer, M. E., Tora, L., Vergezac, A., and Chambon, P. Mechanisms of antihormone action. J. Steroid Biochem. Mol. Biol., 41: 217-221, 1992.
5. Gottardis, M. M., Jiang, S. Y., Jeng, M. H., and Jordan, V. C. Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res., 49: 4090-4093, 1989.
6. Osborne, C. K., Coronado Heinsohn, E. B., Hilsenbeck, S. G., McCue, B. L., Wakeling, A. E., McClelland, R. A., Manning, D. L., and Nicholson, R. I. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J. Natl. Cancer Inst., 87: 746-750, 1995.
7. Tremblay, A., Tremblay, G. B., Labrie, C., Labrie, F., and Giguère, V. EM-800, a novel antiestrogen, acts as a pure antagonist of the transcriptional functions of estrogen receptors a and β. Endocrinology, 139: 111-118, 1998.
8. Tremblay, G. B., Tremblay, A., Copeland, N. G., Gilbert, D. J., Jenkins, N. A., Labrie, P., and Giguere, V. Cloning, chromosomal localization and functional analysis of the murine estrogen receptor β. Mol. Endocrinol., 11: 353-365, 1997.
9. Tremblay, G. B., Tremblay, A., Labrie, F., and Giguère, V. Dominant activity of activation function-1 (AF-1) and differential stoichiometric requirements for AF-1 and -2 in the estrogen receptor α-β heterodimeric complex. Mol. Cell. Biol., 19: 1919-1927, 1999.
10. Gradishar, W. J., and Jordan, V. C. Clinical potential of new antiestrogens. J. Clin. Oncol., 15: 840-852, 1997.
11. Labrie, C., Martel, C., Dufour, J. M., Lévesque, C., Mérand, Y., and Labrie, F. Novel compounds inhibit estrogen formation and action. Cancer Res., 52: 610-615, 1992.
12. Wakeling, A. E. The future of new pure antiestrogens in clinical breast cancer. Breast Cancer Res. Treat. 21: 1-9, 1993.
13. Gauthier, S., Caron, B., Cloutier, J., Dory, Y. L., Favre, A., Larouche, D., Mailhot, J., Ouellet, C., Schwerdtfeger, A., Leblanc, G., Martel, C., Simard, J., Mérand, Y., Bélanger, A., Labrie, C., and Labrie, F. (S)-(+)-4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)ethoxy] phenyl]-2H-1-benzopyran-3-yl]-phenyl]2,2-dimethylpropanoate (EM-800), a highly potent, specific, and orally active non steroidal antiestrogen. J. Med. Chem., 40: 2117-2122, 1997.
14. Simard, J., Labrie, C., Bélanger, A., Gauthier, S., Singh, S. M., Mérand, Y., and Labrie, F. Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D, ZR-75-1 and MCF-7 human breast cancer cells in vitro. Int. J. Cancer, 73: 104-112, 1997.
15. Martel, C., Provencher, L., Li, X., St-Pierre, A., Leblanc, G., Gauthier, S., Mérand, Y., and Labrie, F. Binding characteristics of novel nonsteroidal antiestrogens to the rat uterine estrogen receptors. J. Steroid Biochem. Mol. Biol., 64: 199-205, 1998.
16. Simard, J., Sanchez, R., Poirier, D., Gauthier, S., Singh, S. M., Mérand, Y., Bélanger, A., Labrie, C., and Labrie, F. Blockade of the stimulatory effect of estrogens, OH-Tamoxifen, OH-Toremifene, Droloxifene and Raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells. Cancer Res., 57: 3494-3497, 1997.
17. Couillard, S., Gutman, M., Labrie, C., Bélanger, A., Candas, B., and Labrie, F. Comparison of the effects of the antiestrogens EM-800 and Tamoxifen on the growth of human breast ZR-75-1 cancer xenografts in nude mice. Cancer Res., 58: 60-64, 1998.
18. Kubota, T., Oka, S., Utsumi, T., Inoue, S., Kuzuoka, M., Suto, A., Arisawa, Y., Ishibiki, K., and Abe, O. Human breast carcinoma (ZR-75-1) serially transplanted into nude mice with reference to estradiol dependency and sensitivity to tamoxifen. Jpn. J. Surg., 19: 446-451, 1989.
19. 5-steroids in the ZR-75-1 human breast cancer cell line. Cancer Res., 46: 4933-4937, 1986.
20. Dauvois, S., Spinola, P. G., and Labrie, F. Additive inhibitory effects of bromocriptine (CB-154) and medroxyprogesterone acetate (MPA) on dimethylbenz(a)anthracene (DMBA)-induced mammary tumors in the rat. Eur. J. Cancer Clin. Oncol., 25: 891-897, 1989.
21. Dauvois, S., Geng, C. S., Lévesque, C., Mérand, Y., and Labrie, F. Additive inhibitory effects of an androgen and the antiestrogen EM-170 on estradiol-stimulated growth of human ZR-75-1 breast tumors in athymic mice. Cancer Res., 51: 3131-3135, 1991.
22. Warri, A. M., Huovinen, R. L., Laine, A. M., Martikainen, P. M., and Harkonen, P. L. Apoptosis in toremifene-induced growth inhibition of human breast cancer cells in vivo and in vitro. J. Natl. Cancer Inst., 85: 1412-1418, 1993.
23. Cameron, A. D., Ritchie, A. A., Langdon, S., Anderson, T. J., and Miller, W. R. Tamoxifen-induced apoptosis in ZR-75-1 breast cancer xenografts antedates tumor regression. Breast Cancer Res. Treat., 45: 99-107, 1997.
24. Teixeira, C., Reed, J. C., and Pratt, M. A. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res., 55: 3902-3907, 1995.
25. Darbre, P., Yates, J., Curtis, S., and King, R. J. Effect of estradiol on human breast cancer cells in culture. Cancer Res., 43: 349-354, 1983.
26. de Launoit, Y., Dauvois, S., Dufour, M., Simard, J., and Labrie, F. Inhibition of cell cycle kinetics and proliferation by the androgen 5α-dihydrotestosterone and antiestrogen N,n-butyl-N-methyl-11-(16′α-chloro-3′,17β-dihydroxy- estra-1′,3′,5′-(10′)triene-7′α-yl) undecanamide in human breast cancer ZR-75-1 cells. Cancer Res., 51: 2797-2802, 1991.
27. Salmon, S. E., and Sartorelli, A. C. Cancer chemotherapy. In: B. G. Katzung (ed.), Basic and Clinical Pharmacology, pp. 823-857. East Norwalk, CT: Appleton and Lange, 1995.
28. Osborne, C. K., Coronado, E. B., Allred, D. C., Wiebe, V., and DeGregorio, M. Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerizalion of trans-4-hydroxytamoxifen. 3. Natl. Cancer Inst., 83: 1477-1482, 1991.
29. Santen, R. J., Manni, A., Harvey, H., and Redmond, C. Endocrine treatment of breast cancer in women. Endocr. Rev., 11: 221-265, 1990.
30. Labrie, F., Cusan, L., Gomez, I. L., Diamond, P., and Bélanger, A. Long-term neoadjuvant and adjuvant combined androgen blockade is needed for efficacy of treatment in localized prostate cancer. Mol. Urol., 1: 253-261, 1997.
31. Prout, G. R., Kliman, B., Daly, J. J., MacLaughlin, R. A., Griffin, P. P., and Young, H. H. Endocrine changes after diethylstilbestrol therapy. Effects on prostatic neoplasm and pituitary-gonadal axis. Urology, 7: 148-155, 1976.
32. Pederson, L. C., Buchsbaum, D. J., Vickers, S. M., Kancharla, S. R., Mayo, M. S., Curiel, D. T., and Stackouse, M. A. Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo. Cancer Res., 57: 4325-4332, 1997.
33. Couillard, S., Labrie, C., Bélanger, A., Candas, B., Pouliot, F., and Labrie, F. Effect of dehydroepiandrosterone and the antiestrogen EM-800 on the growth of human ZR-75-1 breast cancer xenografts. J. Natl. Cancer Inst., 90: 772-778, 1998.
34. Couillard, S., Gutman, M., Labrie, F., Candas, B., and Labrie, C. Effect of combined treatment with the pure antiestrogen EM-800 and radiotherapy on the growth of human ZR-75-1 breast cancer xenografts in nude mice. Cancer Res., 59: 4857-4863, 1999.
35. Daly, R. J., and Darbre, P. D. Cellular and molecular events in loss of estrogens sensitivity in ZR-75-1 and T-47-D human breast cancer cells. Cancer Res., 50: 5868-5875, 1990.
36. Lapointe, J., Foumier, A., Richard, V., and Labrie, C. Androgens down-regulate Bcl-2 proto-oncogene expression in ZR-75-1 human breast cancer cells. Endocrinology, 140: 416-421, 1999.
37. Gamcsik, M. P., Millis, K. K., and Colvin, O. M. Noninvasive detection of elevated glutathione levels in MCF-7 cells resistant to 4-hydroperoxycyclophosphamide. Cancer Res., 55: 2012-2016, 1995.
38. Henderson, I. G. Breast cancer. In: G. P. Murphy, Jr. and R. E. Lenhard, Jr. (eds.), American Cancer Society Textbook of Clinical Oncology, pp. 198-219. Atlanta, GA: American Cancer Society, Inc., 1995.
39. Hortobagyi, G. N., and Buzdar, A. U. Current status of adjuvant systemic therapy for primary breast cancer: progress and controversy. CA Cancer J. Clin., 45: 199-226, 1995.
40. Toma, S., Leonessa, F., Coialbu, T., Nicolo, G., and Rosso, R. Effect of 17β-estradiol on doxorubicin cytotoxicity in human breast cancer cell culture. Anticancer Res., 9: 303-308, 1995.
41. Emerman, J. T., and Siemiatkowski, J. Effects of endocrine regulation of growth of a mouse mammary tumor on its sensitivity to chemotherapy. Cancer Res., 44: 1327-1332, 1984.
42. Kiang, D. T., and Kennedy, B. J. The clinical usefulness of human xenografts in nude mice. Cancer (Phila.), 28: 1202-1210, 1971.
43. Markaverich, B. M., Medina, D., and Clark, J. H. Effects of combination estrogen: cyclophosphamide treatment on the growth of the MXT transplantable mammary tumor in the mouse. Cancer Res., 43: 3208-3211, 1983.
44. Sluyser, M., de Goeij, C. C., and Evers, S. G. Combined endocrine therapy and chemotherapy of mouse mammary tumors. Eur. J. Cancer, 17: 155-159, 1981.
45. Boccardo, F., Rubagotti, A., Bruzzi, P., Cappellini, M., Isola, G., Nenci, I., Piffanelli, A., Scanni, A., Sismondi, P., and Santi, L. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group. J. Clin. Oncol., 8: 1310-1320, 1990.
46. Dombernowsky, P., Brincker, H., Hansen, M., Mouridsen, H. T., Overgaard, M., Panduro, J., Rose, C., Axelsson, C. K., Andersen, J., and Andersen, K. W. Adjuvant therapy of premenopausal and menopausal high-risk breast cancer patients. Present status of the Danish Breast Cancer Cooperative Group Trials 77-B and 82-B. Acta Oncol., 27: 691-697, 1998.
47. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomized trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet, 339: 71-85, 1992.
48. Ingle, J. N., Everson, L. K., Wieand, H. S., Cullinan, S. A., Wold, L. E., Hagen, J. B., Martin, J. K., Krook, J. E., Fitzgibbons, R. G., Foley, J. F., Ahmann, D. L., Pfeifle, D. M., and Green, S. J. Randomized trial to evaluate the addition of Tamoxifen to cyclophosphamide, 5-fluorouracil, prednisone adjuvant therapy in premenopausal women with node-positive breast cancer. Cancer (Phila.), 63: 1257-1264, 1989.
49. Osborne, C. K. Tamoxifen in the treatment of breast cancer. N. Engl. J. Med., 339: 1609-1618, 1998.
50. Tormey, D. C., Gray, R., Gilchrist, K., Grage, T., Carbone, P. P., Wolter, J., Woll, J. E., and Cummings, F. J. Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. An Eastern Cooperative Oncology Group trial. Cancer (Phila.), 65: 200-206, 1990.
51. Early Breast Trialist's Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N. Engl. J. Med., 319: 1681-1692, 1988.
52. Fisher, B., Gignam, J., Wolkman, N., DeCillis, A., Emir, B., Wickerham, D. L., Bryant, J., Dimitrov, N. V., Abramson, N., Atkins, J. N., Shibata, H., Deschenes, L., and Margolese, R. G. Tamoxifen and chemotherapy for lymph node-negative estrogen receptor-positive breast cancer. J. Natl. Cancer Inst., 89: 1673-1682, 1997.